Aurinia Pharmaceuticals Hits New 52-Week High of $16.20

Aurinia Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 16.20 on November 4, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it has demonstrated impressive growth metrics.
Over the past year, Aurinia's stock has surged by 164.26%, significantly outperforming the S&P 500, which recorded a 19.89% increase during the same period. The company's market capitalization stands at USD 1,619 million, classifying it as a small-cap entity. With a price-to-earnings ratio of 19.00 and a return on equity of 23.13%, Aurinia showcases a robust financial profile.

The company has consistently reported positive results, with net sales growth of 12.08% and profits rising by 202.3% over the last year. Additionally, Aurinia has maintained a high institutional ownership rate of 50.21%, reflecting confidence from larger investors. With a solid operating cash flow of USD 92.59 million and a favorable interest coverage ratio, Aurinia Pharmaceuticals continues to solidify its position in the market.